Synlett 2009(16): 2688-2690  
DOI: 10.1055/s-0029-1217757
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

A Further Improved Synthesis of a Dibenzodioxocinone CETP Inhibitor

Zhi-Hua Sun*a,b, Guo-Qiang Linb, Erkang Fan*a
a Department of Biochemistry, University of Washington, Seattle, WA 98155, USA
Fax: +1(206)6857002; e-Mail: erkang@u.washington.edu; e-Mail: sungaris@gmail.com;
b Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Feng Lin Road, Shanghai 200032, P. R. of China
Further Information

Publication History

Received 27 April 2009
Publication Date:
03 September 2009 (online)

Abstract

A newly improved synthesis of a dibenzodioxocinone CETP inhibitor is described. Key features of the synthetic route include a chiral ligand induced alkyl addition to aldehyde and the use of triethylborane for improved selective alkylation of brominated phenyl ring.

    References and Notes

  • 1 Sassa T. Niwa G. Unno H. Ikeda M. Miura Y. Tetrahedron Lett.  1974,  45:  3941 
  • 2 inventors; WO  1994012175. Taisho Pharmaceutical Ltd.;
  • 3 Tomoda H. Nishida H. Masuma R. Cao J. Okuda S. Omura S. J. Antibiot.  1990,  44:  136 
  • 4 Salituro GM. Pettibone DJ. Clineschmidt BV. Williamson JM. Zink DL. Bioorg. Med. Chem. Lett.  1993,  3:  337 
  • 5a inventors; DE  4039860. Bayer AG;
  • 5b inventors; EP  0411268. Bayer AG;
  • 6 Bruckner D. Hafner F.-T. Li V. Schmeck C. Telser J. Valalopoulos A. Wirtz G. Bioorg. Med. Chem. Lett.  2005,  15:  3611 
  • 7a Dullaart RPF. Dallinga-Thie GM. Wolffenbuttel BHR. van Tol A. Eur. J. Clin. Invest.  2007,  37:  90 
  • 7b Linsel-Nitschke P. Tall AR. Nature Rev. Drug Discov.  2005,  4:  193 
  • 8 inventors; WO  2004039453. Bayer HealthCare AG;
  • 9 inventors; CN  101066967. Fudan University;
  • 12a King AO. Okukado N. Negishi E. J. Chem. Soc., Chem. Commun.  1977,  683 
  • 12b Handbook of Organo-palladium Chemistry for Organic Synthesis   Part III, Vol. 1:  Negishi E. Wiley-Interscience; New York: 2002. 
  • 13 Stille JK. Angew. Chem., Int. Ed. Engl.  1986,  25:  508 
10

Experimental Procedure To a stirred solution of 4c (74.1 mg, 0.4 mmole) in dry toluene at 15 ˚C under argon, a solution of 2,2-dimethyl-propyl zinc (4.76 g, 23 mmole) in toluene was added. After 15 min, the temperature was lowered to -78 ˚C, followed by the addition of a toluene solution (10 mL) of compound 3 (10.4 g, 18.8 mmol). The mixture was allowed to slowly warm to 0 ˚C, and stirred for another 6 h. The reaction was slowly quenched by a sat. solution of NH4Cl, and then extracted three times with EtOAc. The combined organic phase was washed by H2O and brine, dried over anhyd MgSO4, filtered and concentrated. The product 5 was purified using silica gel chromatography (CH2Cl2-EtOAc, 50:1). Yield 7.06 g, 60%, [a]D ²0 +22.5 (c 1.0, CHCl3; >99% ee, as analyzed by chiral HPLC, see Figure  [²] ). ESI-MS:
m/z = 627.1 [M + H]+. ¹H NMR (400 MHz, CD3Cl): δ = 1.01 (s, 9 H), 1.20-1.70 (m, 8 H), 2.02 (s, 1 H), 2.37 (s, 3 H), 3.45 (m, 1 H), 3.86 (s, 3 H), 3.92 (s, 3 H), 4.50 (dd, 1 H), 4.65 (m, 1 H), 4.93 (dd, 1 H), 5.02 (s, 2 H), 5.08 (m, 1 H), 6.38 (d, 1 H), 6.90 (s, 1 H), 7.18-7.35 (m, 6 H) ppm. ¹³C NMR (100 MHz, CD3Cl): δ = 20.4, 20.5, 25.4, 27.1, 30.1 (3 C), 30.5, 51.5, 52.4, 58.6, 62.3, 63.3, 66.5, 71.1, 114.5, 116.9, 118.8, 121.3, 123.6, 127.1 (2 C), 127.6, 128.9 (2 C), 131.0, 131.6, 131.8, 136.7, 138.3, 142.3, 144.1, 151.1, 154.2, 168.2 ppm.

11

Under argon, compound 10 (18.0 g, 36 mol), CsOAc (35.2 g, 108 mmol), and Pd(dppf)2Cl2 (0.54 g, 0.72 mmol) was dissolved in dry THF. To this was added a solution of Et3B (1 M, 108 mL, 108 mmol) in THF. The mixture was heated to reflux for 4 h. Then it was cooled to 0 ˚C, and the reaction was quenched with 10% NaOH and 30% H2O2. After stirring at r.t. for 30 min, the mixture was neutralized with diluted HCl, followed by extraction with EtOAc for three times. The combined organic phase was washed with brine, dried over anhyd MgSO4, and concentrated. Purification using silica gel chromatography (PE-EtOAc, 8:1 to 1:1) afforded 11. Yield 10.5 g (65%). HRMS (MALDI/DHB): m/z = 471.1550 [M + Na]+. ¹H NMR (400 MHz, CD3Cl): δ = 1.03 (s, 9 H), 1.15 (t, 3 H), 1.57 (m, 1 H), 1.61 (m, 1 H), 1.93 (d, 1 H), 2.31 (s, 3 H), 2.77 (q, 2 H), 3.99 (s, 3 H), 5.16 (m, 1 H), 5.37 (dd, 1 H), 5.48 (dd, 1 H), 6.26 (s, 1 H), 6.84 (d, 1 H), 6.95 (s, 1 H), 7.59 (d, 1 H) ppm. ¹³C NMR (100 MHz, CD3Cl): δ = 13.3; 16.2; 20.7, 30.1 (3 C), 30.8, 52.4, 62.3, 65.9, 66.6, 116.9, 118.8, 121.3, 123.6, 131.0, 131.6, 131.8, 138.3, 142.3, 144.1, 151.1, 154.2, 167.4 ppm.